Incyte Corp logo

Incyte Corp

€ 69.31 (-1.46%) Oct 5
P/E:
16.35
P/B:
3.77
Market Cap:
€ 15.48B ($ 15.16B)
Enterprise V:
€ 12.80B ($ 12.54B)
Volume:
-
Avg Vol (2M):
-
Also Trade In:
Volume:
-
Market Cap €:
15.48B
Market Cap $:
15.16B
PE Ratio:
16.35
Avg Vol (2-Month):
-
Enterprise Value €:
12.80B
Enterprise Value $:
12.54B
PB Ratio:
3.77
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Financials (Next Earnings Date:2022-11-02 Est.)

STU:ICY's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 2,982.623
EPS (TTM) (€) 3.78
Beta 0.25
Volatility % 25.99
14-Day RSI 48.46
14-Day ATR (€) 1.004835
20-Day SMA (€) 69.0325
12-1 Month Momentum % 24.52
52-Week Range (€) 54.22 - 81.33
Shares Outstanding (Mil) 222.43

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Incyte Corp Filings

Document Form Filing Date
No Filing Data

Incyte Corp Analysis

Share your research